Anti-B-cell CAR-T therapy in multiple sclerosis is simply a more profound immunoablation? No
- 29 August 2025
- journal article
- Published by SAGE Publications in Multiple Sclerosis Journal
Abstract
No abstract availableThis publication has 10 references indexed in Scilit:
- Local immune effector cell-associated toxicity syndrome in CAR T-cell treated patients with autoimmune disease: an observational studyThe Lancet Rheumatology, 2025
- CAR T cells in autoimmunity: game changer or stepping stone?Blood, 2025
- CD19-Directed CAR T Cell Therapy in 4 Patients with Refractory Multiple SclerosisBlood, 2024
- CD19-CAR T-cell therapy induces deep tissue depletion of B cellsAnnals of the Rheumatic Diseases, 2024
- The Role of Chimeric Antigen Receptor T‐Cell Therapy in Immune‐Mediated Neurological DiseasesAnnals of Neurology, 2024
- CD19 CAR T-Cell Therapy in Autoimmune Disease — A Case Series with Follow-upNew England Journal of Medicine, 2024
- Innovative cellular therapies for autoimmune diseases: expert-based position statement and clinical practice recommendations from the EBMT practice harmonization and guidelines committeeeClinicalMedicine, 2024
- Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosusNature Medicine, 2022
- Changes of T Lymphocyte Subsets after CAR-T Cell Therapy and Its Clinical SignificanceBlood, 2018
- T cell exclusion, immune privilege, and the tumor microenvironmentScience, 2015